NEW! See our reimagined interface 🙌🏼 Explore now →
DoseMe Cohere makes it fast and easy to identify
patients receiving vancomycin therapy who require
Managing a high volume of patients receiving vancomycin therapy can be a challenge on both time and resources for the provider, as well as at a health-system level.
DoseMe Cohere supports sophisticated surveillance of your patient population allowing you to improve the safety, therapeutic outcomes, and costs associated with vancomycin therapy.
Designed to support clinical pharmacy and quality management teams, DoseMe Cohere allows you to quickly identify at-risk patients in real-time. Using the evidence-based machine learning intelligence behind DoseMeRx, DoseMe Cohere identifies vancomycin patients at risk of a potential adverse drug event or treatment failure using laboratory results such as serum creatinine and predicts whether any future doses will be sub- or supra-therapeutic.
Easily visualize and benchmark sites to identify inconsistencies in treatment outcomes and isolate higher risk areas that may require additional resources. Quickly produce compliance reporting and comparative analytics across units and multiple sites in seconds.
DoseMe Cohere evaluates a wide range of identified risk factors for each patient, allowing pharmacists to quickly identify relevant factors to drive a timely intervention. By extracting patient data including weight, age, height, medication history, and vancomycin drug concentrations, DoseMeRx builds a predictive model of each patient’s response to vancomycin therapy. When this data is combined with charted orders, DoseMe Cohere can predict the exposure and pharmacokinetic outcome days before the dose is administered.
DoseMe Cohere works by applying DoseMeRx’s machine learning in a predictive framework. DoseMe Cohere builds an individual model of each patient and predicts the outcome of medication orders before they’re administered – allowing intervention before any potential problem occurs.